The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. NewAmsterdam Pharma Company NV shares valued at $5,598,975 were purchased by Douglas F Kling on May 15 ’25. At $18.75 per share, Douglas F Kling acquired 298,612 shares.
Also, NAP PoolCo B.V. purchased 1,433,193 shares, netting a total of over 21,669,878 in proceeds.
Before that, Topper James N had added 1,135 shares to its account. In a trade valued at $25,521, the Director bought NewAmsterdam Pharma Company NV shares for $22.49 each. Upon closing the transaction, the insider’s holdings increased to 1,135 shares, worth approximately $63.38 million.
As published in their initiating research note from Stifel on June 10, 2025, NewAmsterdam Pharma Company NV [NAMS] has been a Buy and the price target has been revised to $44. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in early June. As of December 30, 2024, H.C. Wainwright has initiated its “Buy” rating for NAMS. Earlier on May 15, 2024, TD Cowen initiated its rating. Their recommendation was “a Buy” for NAMS stock.
Analyzing NAMS Stock Performance
On last trading session,, NewAmsterdam Pharma Company NV [NASDAQ: NAMS] rose 2.59% to $21.03. The stock’s lowest price that day was $20.1554, but it reached a high of $21.71 in the same session. During the last five days, there has been a surge of approximately 7.79%. Over the course of the year, NewAmsterdam Pharma Company NV shares have dropped approximately -18.17%.
Support And Resistance Levels for NewAmsterdam Pharma Company NV (NAMS)
RSI (Relative Strength Index) is 62.00 on the 14-day chart, showing neutral technical sentiment.
Is NewAmsterdam Pharma Company NV subject to short interest?
Stocks of NewAmsterdam Pharma Company NV saw a sharp rise in short interest on 2025-05-30 jumping by 1.14 million shares to 6.56 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 5.42 million shares. A jump of 17.33% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.35 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.35.
Which companies own the most shares of NewAmsterdam Pharma Company NV (NAMS)?
In terms of NewAmsterdam Pharma Company NV share price expectations, FactSet research, analysts set an average price target of 44.5 in the next 12 months, up nearly 117.07% from the previous closing price of $20.50. Analysts anticipate NewAmsterdam Pharma Company NV stock to reach 48 by 2025, with the lowest price target being 41. In spite of this, 1 analysts ranked NewAmsterdam Pharma Company NV stock as Buy at the end of 2025. On March 14, 2024, Scotiabank assigned a price target of “a Sector outperform” to the stock and initiated coverage with a $35.
